©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Urol. Jul 24, 2016; 5(2): 75-79
Published online Jul 24, 2016. doi: 10.5410/wjcu.v5.i2.75
Published online Jul 24, 2016. doi: 10.5410/wjcu.v5.i2.75
Efficacy and safety of onabotulinum toxin A for overactive bladder
Chintan K Patel, Arthur P Mourtzinos, Institute of Urology, Lahey Hospital and Medical Center, Burlington, MA 01805, United States
Author contributions: Patel CK played an integral role in the conception of the article, acquisition of literature and also drafted the manuscript; Mourtzinos AP is the senior author who reviewed and made critical revisions to the manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest regarding this manuscript.
Correspondence to: Chintan K Patel, MD, Resident in Urology, Institute of Urology, Lahey Hospital and Medical Center, 41 Burlington Mall Rd., Burlington, MA 01805, United States. chintan.patel@lahey.org
Telephone: +1-781-7445100
Received: March 17, 2016
Peer-review started: March 19, 2016
First decision: May 17, 2016
Revised: May 26, 2016
Accepted: July 11, 2016
Article in press: July 13, 2016
Published online: July 24, 2016
Processing time: 130 Days and 2.7 Hours
Peer-review started: March 19, 2016
First decision: May 17, 2016
Revised: May 26, 2016
Accepted: July 11, 2016
Article in press: July 13, 2016
Published online: July 24, 2016
Processing time: 130 Days and 2.7 Hours
Core Tip
Core tip: Overactive bladder (OAB) remains a highly prevalent and frequently, a recalcitrant constellation of symptoms. For patients who are refractory to oral medical therapy, there is sufficient level I evidence to support the use of onabotulinum toxin A injection therapy. It is a safe and very effective 2nd line treatment for OAB, even in the elderly population. The suggested Food and Drug Administration approved dose is 100 U to maximize the benefits and minimize the adverse effects of this therapy. Risks of the intradetrusor injection of onabotulinum toxin A include urinary tract infection, increased post void residual, urinary retention which may lead to necessity of self catherization for a period of time.